Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 7/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20837283 | 0.76 | NQO2 (0.41) | ALDH1A1KDM4ENQO2MAOA | |
| SCHEMBL20837272 | 0.75 | NQO2 (0.40) | ALDH1A1IMPDH2IMPDH1KDM4ENQO2 | |
| SCHEMBL6952678 | 0.75 | NQO2 (0.49) | ALDH1A1KDM4ENQO2 | |
| SCHEMBL20837263 | 0.75 | ALDH1A1 (0.43) | ALDH1A1KDM4EUSP2NQO2GAA | |
| SCHEMBL22439179 | 0.74 | SCN9A (0.39) | AR | |
| SCHEMBL22439194 | 0.73 | ALDH1A1 (0.42) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL31330696 | 0.73 | ALDH1A1 (0.49) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL20837299 | 0.71 | NQO2 (0.37) | ALDH1A1KDM4ENQO2MAOAMAOB | |
| SCHEMBL20837066 | 0.71 | MCL1 (0.38) | ALDH1A1KDM4ENQO2MAOAMAOB | |
| SCHEMBL20837063 | 0.71 | KDM4E (0.33) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | ALDH1A1 1246/4885IMPDH2 1313/4885IMPDH1 1452/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | ALDH1A1 1246/4885IMPDH2 1313/4885IMPDH1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.